Second malignancy risk associated with treatment of Hodgkin's lymphoma: Meta-analysis of the randomised trials Review uri icon

Overview

MeSH Major

  • Hodgkin Disease
  • Neoplasms, Second Primary
  • Randomized Controlled Trials as Topic

abstract

  • Administration of CT in addition to RT as initial therapy for HL decreases overall SMR by reducing relapse and need for salvage therapy. Administration of RT additional to CT marginally increases overall SMR in advanced stages. Breast cancer risk (but not SMR in general) was substantially higher after EF-RT. Caution is needed in applying these findings to current therapies.

publication date

  • December 2006

Research

keywords

  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1093/annonc/mdl302

PubMed ID

  • 16984979

Additional Document Info

start page

  • 1749

end page

  • 60

volume

  • 17

number

  • 12